ESR1 and breast carcinoma: In the clinical trial known as VERITAC, ARV‐471 contributed to potent efficacy and manageable safety profiles in patients with locally advanced or metastatic ER+/HER2− breast cancer who had prior CDK4/6i therapy [219, 220].